cysteine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
769 52-90-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cysteine
  • L-Cysteine
  • cysteine hydrochloride
  • cysteine HCl
A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.
  • Molecular weight: 121.15
  • Formula: C3H7NO2S
  • CLOGP: -2.35
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 63.32
  • ALOGS: -0.72
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 1986 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 14.20 0 3 16 9525 2348541

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 37.51 0 7 12 8163 1738599

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bronchiectasis indication 12295008 DOID:9563
Amyloidosis indication 17602002 DOID:9120
Bronchitis indication 32398004 DOID:6132
General anesthesia indication 50697003
Poisoning by acetaminophen indication 70273001
Cystic fibrosis of the lung indication 86555001
Thick Bronchial Secretions indication
Contrast Media-Induced Nephrotoxicity Prevention indication
Atelectasis due to Mucous Obstruction indication
Meconium ileus off-label use 206523001
Bronchial Studies off-label use
Bronchospasm contraindication 4386001
Classical phenylketonuria contraindication 7573000
Peptic ulcer contraindication 13200003 DOID:750
Esophageal varices contraindication 28670008
Gastrointestinal ulcer contraindication 40845000
Low blood pressure contraindication 45007003
Gastrointestinal hemorrhage contraindication 74474003
Decreased respiratory function contraindication 80954004
Acute exacerbation of asthma contraindication 708038006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.82 acidic
pKa2 10.19 acidic
pKa3 8.8 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
500MG/10ML (50MG/ML) ELCYS EXELA PHARMA SCS LLC N210660 April 16, 2019 RX SOLUTION INTRAVENOUS 10478453 Jan. 15, 2039 METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION
500MG/10ML (50MG/ML) ELCYS EXELA PHARMA SCS LLC N210660 April 16, 2019 RX SOLUTION INTRAVENOUS 10583155 Jan. 15, 2039 METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION
500MG/10ML (50MG/ML) NOURESS AVADEL LEGACY N212535 Dec. 13, 2019 RX SOLUTION INTRAVENOUS 10543186 March 15, 2039 METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cystine/glutamate transporter Transporter Ki 4.23 CHEMBL

External reference:

IDSource
D003545 MESH_DESCRIPTOR_UI
4031437 VUID
N0000184609 NUI
C0010654 UMLSCUI
D00026 KEGG_DRUG
108949008 SNOMEDCT_US
5932006 SNOMEDCT_US
4019702 VANDF
4031437 VANDF
004536 NDDF
3024 RXNORM
7452 MMSL
d04181 MMSL
11233 MMSL
5862 PUBCHEM_CID
CHEBI:15356 CHEBI
CHEMBL863 ChEMBL_ID
CHEMBL54943 ChEMBL_ID
DB00151 DRUGBANK_ID
CHEMBL1200630 ChEMBL_ID
K848JZ4886 UNII
6162 INN_ID
7048-04-6 SECONDARY_CAS_RN
4782 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NephrAmine HUMAN PRESCRIPTION DRUG LABEL 10 0264-1909 INJECTION, SOLUTION 0.01 g INTRAVENOUS NDA 13 sections
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.01 g INTRAVENOUS NDA 13 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9010 INJECTION, SOLUTION 0.02 g INTRAVENOUS NDA 13 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9011 INJECTION, SOLUTION 0.02 g INTRAVENOUS NDA 13 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.02 g INTRAVENOUS NDA 12 sections
FreAmine HBC HUMAN PRESCRIPTION DRUG LABEL 15 0264-9350 INJECTION, SOLUTION 0.01 g INTRAVENOUS NDA 13 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.02 g INTRAVENOUS NDA 12 sections
HepatAmine HUMAN PRESCRIPTION DRUG LABEL 16 0264-9371 INJECTION, SOLUTION 0.01 g INTRAVENOUS NDA 13 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1130 INJECTION, SOLUTION 0.02 g INTRAVENOUS ANDA 12 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1131 INJECTION, SOLUTION 0.01 g INTRAVENOUS ANDA 12 sections
L-Cysteine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-8940 INJECTION, SOLUTION 50 mg INTRAVENOUS Unapproved drug other 11 sections
ELCYS HUMAN PRESCRIPTION DRUG LABEL 1 51754-1007 INJECTION, SOLUTION 10 mg INTRAVENOUS NDA 14 sections
Viatrexx-Pigmentation HUMAN PRESCRIPTION DRUG LABEL 9 73069-410 INJECTION 31 [kp_C] INTRAVENOUS unapproved drug other 11 sections
Nouress HUMAN PRESCRIPTION DRUG LABEL 1 76014-006 INJECTION 34.50 mg INTRAVENOUS NDA 14 sections